MONTREAL, QUEBEC -- (MARKET WIRE) -- April 03, 2007 -- IBEX Technologies Inc. (TSX: IBT) today announced that it has released for sale to the pharmaceutical research market the new C2C Urine ELISA kit. The new assay for C2C, a cartilage breakdown product, is similar to the current IBEX C2C ELISA but has been re-engineered to better detect the smaller peptides found in urine.
